Physician profile
Brian G Lee
NPI 1619123528
$8,155.16
in general payments reported to CMS, 2019-2025
25 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,352 · 2020: $782 · 2021: $635 · 2022: $251 · 2023: $181 · 2024: $481 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,923.82 | 2019-2021 | |
| Stryker Corporation | $1,397.80 | 2019-2023 | Scopis Ent |
| Globus Medical, INC. | $801.12 | 2019 | |
| Medical Device Business Services, INC. | $486.77 | 2019 | |
| Lima USA, INC. | $357.14 | 2020 | |
| Genzyme Corporation | $334.32 | 2021-2025 | |
| Nevro Corp. | $275.68 | 2019-2022 | |
| Glaxosmithkline, LLC. | $210.39 | 2023-2025 | Nucala |
| Vertos Medical, INC. | $175.21 | 2021 | |
| Aerin Medical INC. | $171.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $156.12 | 2021-2025 | Dupixent |
| Optinose US, INC. | $133.87 | 2022-2024 | |
| Nuvasive, INC. | $112.44 | 2020 | |
| Shire North American Group INC | $110.74 | 2019 | |
| Kaleo, INC. | $86.69 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $78.49 | 2024 | Korlym |
| Zimmer Biomet Holdings, INC. | $77.81 | 2020 | |
| Acclarent, INC | $75.99 | 2019 | |
| Phadia US INC. | $53.70 | 2024 | Immunocap |
| Neurent Medical Limited | $28.50 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Alphatec Spine, INC | $26.33 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.38 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $23.31 | 2025 | Neffy |
| Amgen INC. | $16.42 | 2025 | Tezspire |
| Medtronic, INC. | $16.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.